Clinical Advances in the Treatment and Management of Pulmonary Arterial Hypertension (PAH)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2019 to December 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Actelion

Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder where continuous, exceedingly high blood pressure exists in the pulmonary artery – the blood vessel that carries blood from the right ventricle of the heart into the small arteries in the lungs. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure – the most common cause of death for PAH patients. Though relatively rare PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Additionally, PAH often leads to the onset of co-morbidities associated with the disease. Accurate classification and early diagnosis and are essential to managing the disease and its associated costs. There are several treatments for PAH depending on the severity and the patient’s profile. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Treatment guidelines continue to be updated. Because of the rarity of PAH, clinicians need to understand the risk factors and symptoms of the disease, along with the importance of diagnosing the patient in the appropriate class, so as to apply treatment algorithms accordingly for pharmacologic decisions.

Upon completion of this activity, participants will be able to:

  • Analyze the clinical trial data for current and emerging therapeutics for the management of pulmonary arterial hypertension (PAH)

  • Discuss the diagnostic tools that will improve chances for an early and accurate diagnosis of PAH

  • Assess the current pharmacotherapies in relation to the updated guidelines and recommended treatment algorithms

  • Explore the role of monotherapy and combination therapy in PAH management and the impact their role can have in improving outcomes

  • Examine the challenges of adverse events and comorbidities with PAH therapies and strategies to improve patient adherence
     

Faculty: Murali M. Chakinala, MD
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Director, Pulmonary Hypertension Center
Washington University School of Medicine

Disclosure:

Dr. Chakinala serves on an advisory board for Actelion, Arena, Bayer, Express Scripts, and United Therapeutics. He serves as a consultant for Akros, Arena, Phase Bio, and Reata. He has received grant/research support from Actelion, Arena, Bayer, Eiger, Liquidia, Medtronic, Novartis, Phase Bio, and Reata. He serves on the speaker's bureau for Bayer and Gilead. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from Actelion

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue